FDA Recommends Narrowed Indication For EDAP’s Ablatherm-HIFU
This article was originally published in The Gray Sheet
Executive Summary
The agency sent EDAP TMS a not-approvable letter for its high intensity focused ultrasound device, asking the company to narrow its sought prostate cancer indication and provide additional safety and efficacy data by next spring.
You may also be interested in...
US FDA Asks Prostate Ablation Device-Sponsors For More Clinical Safety Data To Support Clearances
Almost four years after the agency first authorized a prostate ablation device, regulators have proposed a number of requirements for clinical studies that sponsors would have to meet to comply with special controls needed for the devices to be cleared for marketing.
FDA Panel Rejects Sonablate 450 HIFU Device For Prostate Cancer
The advisors voted almost unanimously that SonaCare Medical’s HIFU device did not have good enough data to support a positive risk-benefit profile, but they suggested the company could improve their trial design and try again.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.